Overview
Heart or Lung Conundrums: Unleash Your Diagnostic Skills
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Did you know that shortness of breath, difficulty exercising, fatigue, and cold hands and feet could indicate a serious health concern? When your patients present with these symptoms, could it be indicating a more serious heart or lung disease? Put your skills to the test! In just 15 minutes, navigate through real-world cases to see if you can correctly diagnose each patient. Diagnostic conclusions are revealed after reviewing all cases. Hear faculty insights on the implications of learner decisions along with rationales for appropriate next steps to aid in making a final diagnosis. Hear evidence-based treatment strategies recommended for the patients following the diagnoses. Apply the latest scientific evidence into evolving treatment plans and improve the management of your patients today!
This program is intended for cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons, primary care practitioners (physicians, NPs, PAs), and pediatricians.
Cardiac and pulmonary diseases are characterized by an enormous diversity in clinical course and characteristics, but early symptoms of many of these diseases are similar and often nonspecific, including fatigue, shortness of breath, chest pain, and exercise difficulty. Consequently, many patients may go undiagnosed for many years, indicating the need for improved diagnosis in primary care and specialty settings. Due to the nuances and heterogeneity of these conditions in addition to practice-changing therapies that are now available for burdened patients, this educational course will provide clinicians with strategies to facilitate timely diagnoses, optimize novel therapies, and improve transition of care models.
Upon completion of this activity, learners will be able to:
• Implement evidence-based strategies to facilitate prompt and accurate diagnosis of cardiac and/or pulmonary diseases
• Evaluate safety and efficacy data of therapies for cardiac and/or pulmonary diseases
• Apply the latest scientific evidence into evolving treatment plans for cardiac and/or pulmonary diseases
• Implement evidence-based strategies to facilitate prompt and accurate diagnosis of cardiac and/or pulmonary diseases
• Evaluate safety and efficacy data of therapies for cardiac and/or pulmonary diseases
• Apply the latest scientific evidence into evolving treatment plans for cardiac and/or pulmonary diseases
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Bristol Myers Squibb.
Anjali Owens, MD
Associate Professor of Medicine
University of Pennsylvania Perelman School of Medicine
Director, Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA
Associate Professor of Medicine
University of Pennsylvania Perelman School of Medicine
Director, Center for Inherited Cardiovascular Disease
University of Pennsylvania
Philadelphia, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Anjali Owens, MD
Sources of Funding for Research: Bristol Myers Squibb
Consulting Agreements: Biomarin, Bristol Myers Squibb, Cytokinetics, Edgewise, Tenaya
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Beta-blockers, calcium channel blockers, disopyramide, anticoagulants, amiodarone, sotalol, dofetilide, diuretics, albuterol inhalers, ACE inhibitors, angiotensin receptor blockers, diuretics, cardiac myosin inhibitors, SGLT2 inhibitors, cardiac mitotropes, and copper chelating agents are not approved for the treatment of certain cardiac or pulmonary conditions.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, learners are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
